Chemicals and materials / Pharmaceutical materials
BASF: Recommending formulation candidates
- Company
- BASF
- Country
- Germany
- Adoption stage
- In operation
- Source published
- Date basis
- The date the source was published. It can differ from the date adoption started.
- How the source was checked
- Read the full source text
The work problem
Developing a single new drug takes years, from early research through clinical trials to regulatory review and approval. Formulation scientists had to pick out the excipients for liquid, semi-solid and solid products themselves. BASF wanted to simplify that process and bring it forward.
Technology and data
BASF Pharma Solutions built the digital platform ZoomLab. It is an AI-supported tool developed with machine learning among other technologies. It helps formulation scientists find suitable excipients and predicts and optimises a composition immediately. Users work with a large excipient and formulation database holding materials from BASF and platform partners. They can also order samples directly without sending drug chemistry information outside. The final choice is made by the formulation scientist. The source states that the tool works by supporting the scientist.
Results
BASF explained that ZoomLab can meaningfully reduce time spent in the laboratory and development cost. It said the path to laboratory testing becomes faster. Training material and scientific and technical support from BASF experts are provided alongside.
Limits and open questions
The source gives no figures for how much time or cost was reduced. Nor does it state that the tool replaced experimental verification.
Sources
- Putting AI to work: five BASF success storiesbasf.com, Accessed
Compiled from public sources. These are not results from ATF Works customers.